| Dr Hajoon Chun, MD | |
|
14601 45th Ave, Suite 404, Flushing, NY 11355-2200 | |
| (718) 670-3143 | |
| (718) 321-6196 |
| Full Name | Dr Hajoon Chun |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 33 Years |
| Location | 14601 45th Ave, Flushing, New York |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174612592 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207VM0101X | Obstetrics & Gynecology - Maternal & Fetal Medicine | 198540 (New York) | Primary |
| Entity Name | Tjh Medical Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184670465 PECOS PAC ID: 8527960533 Enrollment ID: O20040121000802 |
News Archive
In a letter published Wednesday in the Lancet, officials from the CDC refute "point by point" three letters previously published in the journal that were critical of the agency's Center for Global Health, ScienceInsider reports.
Progress made in the technology development for studying protein-DNA interactions, conducted by Chang Lu, associate professor of chemical engineering and a core faculty member of the School of Biomedical Engineering and Sciences at Virginia Tech, has led to the National Institutes of Health (NIH) awarding a new project to continue his groundbreaking work.
Results from two clinical trials show that patients with early-stage breast cancer who received trastuzumab (Herceptin) in combination with chemotherapy had a 52 percent decrease in risk for breast cancer recurrence, compared with patients who received the same chemotherapy without the drug. The difference is statistically highly significant.
Adamis Pharmaceuticals Corporation (OTCBB: ADMP) today announced the completion of the acquisition of a unique patented cancer vaccine technology from the Regents of the University of California.
› Verified 9 days ago
| Entity Name | Flushing Hospital & Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548217763 PECOS PAC ID: 2668367483 Enrollment ID: O20040219000415 |
News Archive
In a letter published Wednesday in the Lancet, officials from the CDC refute "point by point" three letters previously published in the journal that were critical of the agency's Center for Global Health, ScienceInsider reports.
Progress made in the technology development for studying protein-DNA interactions, conducted by Chang Lu, associate professor of chemical engineering and a core faculty member of the School of Biomedical Engineering and Sciences at Virginia Tech, has led to the National Institutes of Health (NIH) awarding a new project to continue his groundbreaking work.
Results from two clinical trials show that patients with early-stage breast cancer who received trastuzumab (Herceptin) in combination with chemotherapy had a 52 percent decrease in risk for breast cancer recurrence, compared with patients who received the same chemotherapy without the drug. The difference is statistically highly significant.
Adamis Pharmaceuticals Corporation (OTCBB: ADMP) today announced the completion of the acquisition of a unique patented cancer vaccine technology from the Regents of the University of California.
› Verified 9 days ago
| Entity Name | Bethpage Medical Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205074739 PECOS PAC ID: 3375692387 Enrollment ID: O20090522000032 |
News Archive
In a letter published Wednesday in the Lancet, officials from the CDC refute "point by point" three letters previously published in the journal that were critical of the agency's Center for Global Health, ScienceInsider reports.
Progress made in the technology development for studying protein-DNA interactions, conducted by Chang Lu, associate professor of chemical engineering and a core faculty member of the School of Biomedical Engineering and Sciences at Virginia Tech, has led to the National Institutes of Health (NIH) awarding a new project to continue his groundbreaking work.
Results from two clinical trials show that patients with early-stage breast cancer who received trastuzumab (Herceptin) in combination with chemotherapy had a 52 percent decrease in risk for breast cancer recurrence, compared with patients who received the same chemotherapy without the drug. The difference is statistically highly significant.
Adamis Pharmaceuticals Corporation (OTCBB: ADMP) today announced the completion of the acquisition of a unique patented cancer vaccine technology from the Regents of the University of California.
› Verified 9 days ago
| Entity Name | Onsite Medical Suite Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497131403 PECOS PAC ID: 9931408515 Enrollment ID: O20160503001714 |
News Archive
In a letter published Wednesday in the Lancet, officials from the CDC refute "point by point" three letters previously published in the journal that were critical of the agency's Center for Global Health, ScienceInsider reports.
Progress made in the technology development for studying protein-DNA interactions, conducted by Chang Lu, associate professor of chemical engineering and a core faculty member of the School of Biomedical Engineering and Sciences at Virginia Tech, has led to the National Institutes of Health (NIH) awarding a new project to continue his groundbreaking work.
Results from two clinical trials show that patients with early-stage breast cancer who received trastuzumab (Herceptin) in combination with chemotherapy had a 52 percent decrease in risk for breast cancer recurrence, compared with patients who received the same chemotherapy without the drug. The difference is statistically highly significant.
Adamis Pharmaceuticals Corporation (OTCBB: ADMP) today announced the completion of the acquisition of a unique patented cancer vaccine technology from the Regents of the University of California.
› Verified 9 days ago
| Entity Name | Hjc Medicine Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083126155 PECOS PAC ID: 9739533787 Enrollment ID: O20230926001559 |
News Archive
In a letter published Wednesday in the Lancet, officials from the CDC refute "point by point" three letters previously published in the journal that were critical of the agency's Center for Global Health, ScienceInsider reports.
Progress made in the technology development for studying protein-DNA interactions, conducted by Chang Lu, associate professor of chemical engineering and a core faculty member of the School of Biomedical Engineering and Sciences at Virginia Tech, has led to the National Institutes of Health (NIH) awarding a new project to continue his groundbreaking work.
Results from two clinical trials show that patients with early-stage breast cancer who received trastuzumab (Herceptin) in combination with chemotherapy had a 52 percent decrease in risk for breast cancer recurrence, compared with patients who received the same chemotherapy without the drug. The difference is statistically highly significant.
Adamis Pharmaceuticals Corporation (OTCBB: ADMP) today announced the completion of the acquisition of a unique patented cancer vaccine technology from the Regents of the University of California.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Hajoon Chun, MD 14601 45th Ave, Suite 404, Flushing, NY 11355-2200 Ph: (718) 670-3143 | Dr Hajoon Chun, MD 14601 45th Ave, Suite 404, Flushing, NY 11355-2200 Ph: (718) 670-3143 |
News Archive
In a letter published Wednesday in the Lancet, officials from the CDC refute "point by point" three letters previously published in the journal that were critical of the agency's Center for Global Health, ScienceInsider reports.
Progress made in the technology development for studying protein-DNA interactions, conducted by Chang Lu, associate professor of chemical engineering and a core faculty member of the School of Biomedical Engineering and Sciences at Virginia Tech, has led to the National Institutes of Health (NIH) awarding a new project to continue his groundbreaking work.
Results from two clinical trials show that patients with early-stage breast cancer who received trastuzumab (Herceptin) in combination with chemotherapy had a 52 percent decrease in risk for breast cancer recurrence, compared with patients who received the same chemotherapy without the drug. The difference is statistically highly significant.
Adamis Pharmaceuticals Corporation (OTCBB: ADMP) today announced the completion of the acquisition of a unique patented cancer vaccine technology from the Regents of the University of California.
› Verified 9 days ago
Dr. Yi-ju Amy Chen, MD, MPH Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 5645 Main St, Flushing, NY 11355 Phone: 718-670-2000 | |
Daniel W Skupski, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 5645 Main St # S365, Flushing, NY 11355 Phone: 718-670-1534 Fax: 718-661-7356 | |
Devbala Ramanathan, MDFACOG Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 43-49 Smart Street, Flushing, NY 11355 Phone: 718-886-1525 Fax: 718-661-2244 | |
Ms. Tsz Wan Li, Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 3808 Union St Ste 3g, Flushing, NY 11354 Phone: 718-939-0808 | |
Dr. Gary Scott Eglinton, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 5645 Main St, Flushing, NY 11355 Phone: 718-670-1517 Fax: 516-437-4167 | |
Mrs. Meera I Prabhat, PHYSICIAN PC Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 14416 Holly Ave, Flushing, NY 11355 Phone: 718-445-8994 Fax: 718-445-9035 | |
Christine Ejin Kim, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 131-72 40th Road, Flushing, NY 11354 Phone: 718-886-1287 Fax: 718-886-3903 |